Evidence map›Paper›PMID 35756920›Full record

ArticleFrontiers in neurology2022

The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series.

Andrea Santangelo, Emanuele Bartolini, Giulia Nuzzi, Thomas Foiadelli, Alexandre Michev, Tommaso Mina, Irene Trambusti, Valeria Fichera, Alice Bonuccelli, Gabriele Massimetti and 16 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 1 country.

Andrea SantangeloPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Emanuele BartoliniDepartment of Developmental Neuroscience, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Stella Maris, Pisa, Italy.
Giulia NuzziPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Thomas FoiadelliClinica Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Alexandre MichevClinica Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Tommaso MinaPaediatric Haematology/Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Irene TrambustiPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Valeria FicheraPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Alice BonuccelliPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Gabriele MassimettiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Diego G PeroniPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Emanuela De MarcoPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Luca CoccoliPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Laura LutiPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Sayla BernasconiPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Margherita NardiPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Maria Cristina MenconiPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Gabriella CasazzaPaediatric Oncology and Haematology Department, Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Dario PrunaPaediatric Neurology, Paediatric Department, ARNAS G. Brotzu, Cagliari, Italy.
Rosamaria MuraPaediatric Oncology and Haematology, Pediatric Department, ARNAS G. Brotzu, Cagliari, Italy.
Chiara MarraPaediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Daniele ZamaPaediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Pasquale StrianoPaediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Duccio M CordelliUnitá Operativa Complessa (UOC) Neuropsichiatria dell'età Pediatrica, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Roberta BattiniDepartment of Developmental Neuroscience, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Stella Maris, Pisa, Italy.
Alessandro OrsiniPaediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Azienda Ospedaliera Universitaria Pisana · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITAzienda Ospedaliera G. Brotzu · ITIstituto Giannina Gaslini · ITUniversity of Pisa · ITAzienda USL di Bologna · ITFondazione Stella Maris · ITIstituto delle Scienze Neurologiche di Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Stroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome. Materials and Methods: We retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study. Results: The underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4-34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (± 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (± 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients. Conclusions: SLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management.

Indexed as

methotrexateneurotoxicitypseudo-strokestroke-like syndromesubacute toxicity

Identifiers

PMID35756920
PMCPMC9226576
OpenAlexW4282013153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.